目次

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY
1.1 OVERVIEW

2 MARKET INTRODUCTION
2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE
2.5 ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 SECONDARY RESEARCH
3.3 PRIMARY RESEARCH
3.4 BREAKDOWN OF PRIMARY RESPONDENTS
3.5 FORECASTING TECHNIQUES
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
3.6.1 BOTTOM-UP APPROACH
3.6.2 TOP-DOWN APPROACH
3.7 DATA TRIANGULATION
3.8 VALIDATION

4 MARKET DYNAMICS
4.1 OVERVIEW
4.2 DRIVERS
4.2.1 GROWING PREVALENCE OF RETINAL DISEASES ACROSS THE GLOBE
4.2.2 RISING NUMBER OF STRATEGIC INITIATIVES
4.3 RESTRAINTS
4.3.1 LACK OF AWARENESS REGARDING RETINAL DISEASES
4.4 OPPORTUNITY
4.4.1 INCREASING INITIATIVES BY PUBLIC AND PRIVATE ORGANIZATIONS TO DRIVE AWARENESS REGARDING RETINAL DISEASES

5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN ANALYSIS
5.1.1 R&D
5.1.2 MANUFACTURING
5.1.3 DISTRIBUTION & SALES
5.1.4 POST-SALES MONITORING
5.2 PORTER'S FIVE FORCES MODEL
5.2.1 THREAT OF NEW ENTRANTS
5.2.2 BARGAINING POWER OF SUPPLIERS
5.2.3 THREAT OF SUBSTITUTES
5.2.4 BARGAINING POWER OF BUYERS
5.2.5 INTENSITY OF RIVALRY
5.3 IMPACT OF COVID-19 ON THE RETINA HEALTH MARKET
5.3.1 IMPACT ON SUPPLY CHAIN
5.3.2 IMPACT ON PRODUCTION
5.3.3 IMPACT ON MARKET PLAYERS
5.3.4 IMPACT ON DEMAND

6 GLOBAL RETINA HEALTH MARKET, BY TREATMENT
6.1 OVERVIEW
6.2 DRUGS
6.3 THERAPY
6.3.1 GENE THERAPY
6.3.2 NUTRITION THERAPY
6.3.3 OTHERS
6.4 SURGERY

7 GLOBAL RETINA HEALTH MARKET, BY DISEASE INDICATION
7.1 OVERVIEW
7.2 AGE-RELATED MACULAR DEGENERATION
7.3 DIABETIC RETINOPATHY
7.4 INHERITED RETINAL DISEASES
7.5 RETINOBLASTOMA
7.6 OTHERS

8 GLOBAL RETINA HEALTH MARKET, BY REGION
8.1 OVERVIEW
8.2 NORTH AMERICA
8.2.1 US
8.2.2 CANADA
8.3 EUROPE
8.3.1 GERMANY
8.3.2 UK
8.3.3 FRANCE
8.3.4 ITALY
8.3.5 SPAIN
8.3.6 REST OF EUROPE
8.4 ASIA-PACIFIC
8.4.1 JAPAN
8.4.2 CHINA
8.4.3 INDIA
8.4.4 AUSTRALIA
8.4.5 SOUTH KOREA
8.4.6 REST OF ASIA-PACIFIC
8.5 REST OF THE WORLD
8.5.1 MIDDLE EAST
8.5.2 AFRICA
8.5.3 LATIN AMERICA

9 COMPETITIVE LANDSCAPE
9.1 OVERVIEW
9.2 COMPETITIVE BENCHMARKING
9.3 MAJOR GROWTH STRATEGY IN THE GLOBAL RETINA HEALTH MARKET
9.4 THE LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL RETINA HEALTH MARKET
9.5 KEY DEVELOPMENT ANALYSIS
9.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
9.6.1 PRODUCT LAUNCH/PRODUCT APPROVAL
9.6.2 MERGER & ACQUISITIONS
9.6.3 EXPANSION
9.6.4 AGREEMENT/MARKETING STRATEGIES
9.7 FINANCIAL MATRIX
9.7.1 SALES (USD MILLION), 2021
9.7.2 RESEARCH & DEVELOPMENT EXPENDITURE (USD MILLION), 2021

10 COMPANY PROFILES
10.1 NOVARTIS AG
10.1.1 COMPANY OVERVIEW
10.1.2 FINANCIAL OVERVIEW
10.1.3 PRODUCTS/SERVICES OFFERED
10.1.4 KEY DEVELOPMENTS
10.1.5 SWOT ANALYSIS
10.1.6 KEY STRATEGIES
10.2 SPARK THERAPEUTICS, INC.
10.2.1 COMPANY OVERVIEW
10.2.2 FINANCIAL OVERVIEW
10.2.3 PRODUCTS/SERVICES OFFERED
10.2.4 KEY DEVELOPMENTS
10.2.5 KEY STRATEGIES
10.3 GENSIGHT BIOLOGICS
10.3.1 COMPANY OVERVIEW
10.3.2 FINANCIAL OVERVIEW
10.3.3 PRODUCTS/SERVICES OFFERED
10.3.4 KEY DEVELOPMENTS
10.3.5 KEY STRATEGIES
10.4 ALLERGAN PLC (SUBSIDIARY OF ABBVIE INC.)
10.4.1 COMPANY OVERVIEW
10.4.2 FINANCIAL OVERVIEW
10.4.3 PRODUCTS/SERVICES OFFERED
10.4.4 KEY DEVELOPMENTS
10.4.5 SWOT ANALYSIS
10.4.6 KEY STRATEGIES
10.5 OXFORD BIOMEDICA PLC
10.5.1 COMPANY OVERVIEW
10.5.2 FINANCIAL OVERVIEW
10.5.3 PRODUCTS/SERVICES OFFERED
10.5.4 KEY DEVELOPMENTS
10.5.5 KEY STRATEGIES
10.6 HEMERA BIOSCIENCES LLC
10.6.1 COMPANY OVERVIEW
10.6.2 FINANCIAL OVERVIEW
10.6.3 PRODUCTS/SERVICES OFFERED
10.6.4 KEY DEVELOPMENTS
10.6.5 SWOT ANALYSIS
10.6.6 KEY STRATEGIES
10.7 SANTEN PHARMACEUTICALS INC.
10.7.1 COMPANY OVERVIEW
10.7.2 FINANCIAL OVERVIEW
10.7.3 PRODUCTS OFFERED
10.7.4 KEY DEVELOPMENTS
10.7.5 SWOT ANALYSIS
10.7.6 KEY STRATEGIES
10.8 REGENXBIO INC.
10.8.1 COMPANY OVERVIEW
10.8.2 FINANCIAL OVERVIEW
10.8.3 PRODUCTS OFFERED
10.8.4 KEY DEVELOPMENTS
10.8.5 SWOT ANALYSIS
10.8.6 KEY STRATEGIES
10.9 MEIRAGTX LIMITED
10.9.1 COMPANY OVERVIEW
10.9.2 FINANCIAL OVERVIEW
10.9.3 PRODUCTS OFFERED
10.9.4 KEY DEVELOPMENTS
10.9.5 KEY STRATEGIES
10.10 APPLIED GENETIC TECHNOLOGIES CORPORATION (AGTC)
10.10.1 COMPANY OVERVIEW
10.10.2 FINANCIAL OVERVIEW
10.10.3 PRODUCTS OFFERED
10.10.4 KEY DEVELOPMENTS
10.10.5 KEY STRATEGIES

11 APPENDIX
11.1 REFERENCES
11.2 RELATED REPORTS
?

LIST OF TABLES
TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS
TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
TABLE 3 GLOBAL RETINA HEALTH MARKET, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 4 COMMON RETINA DRUGS
TABLE 5 GLOBAL RETINA HEALTH MARKET, FOR DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 6 GLOBAL RETINA HEALTH MARKET, FOR THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 7 GLOBAL RETINA HEALTH MARKET, FOR THERAPY, BY TYPE, 2018-2030 (USD MILLION)
TABLE 8 GLOBAL RETINA HEALTH MARKET, FOR GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9 GLOBAL RETINA HEALTH MARKET, FOR NUTRITION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 10 GLOBAL RETINA HEALTH MARKET, FOR OTHERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11 GLOBAL RETINA HEALTH MARKET, FOR SURGERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 12 GLOBAL RETINA HEALTH MARKET, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 13 GLOBAL RETINA HEALTH MARKET, FOR AGE-RELATED MACULAR DEGENERATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 14 GLOBAL RETINA HEALTH MARKET, FOR DIABETIC RETINOPATHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 15 GLOBAL RETINA HEALTH MARKET, FOR INHERITED RETINAL DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 16 GLOBAL RETINA HEALTH MARKET, FOR RETINOBLASTOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 17 GLOBAL RETINA HEALTH MARKET, FOR OTHERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18 GLOBAL: RETINA HEALTH MARKET, BY REGION, 2018-2030 (USD MILLION)
TABLE 19 NORTH AMERICA: RETINA HEALTH MARKET, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 20 NORTH AMERICA: RETINA HEALTH MARKET, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 21 NORTH AMERICA: RETINA HEALTH MARKET FOR THERAPY, BY TYPE, 2018-2030 (USD MILLION)
TABLE 22 NORTH AMERICA: RETINA HEALTH MARKET, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 23 US: RETINA HEALTH MARKET, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 24 US: RETINA HEALTH MARKET FOR THERAPY, BY TYPE, 2018-2030 (USD MILLION)
TABLE 25 US: RETINA HEALTH MARKET, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 26 CANADA: RETINA HEALTH MARKET, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 27 CANADA: RETINA HEALTH MARKET FOR THERAPY, BY TYPE, 2018-2030 (USD MILLION)
TABLE 28 CANADA: RETINA HEALTH MARKET, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 29 EUROPE: RETINA HEALTH MARKET, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 30 EUROPE: RETINA HEALTH MARKET, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 31 EUROPE: RETINA HEALTH MARKET FOR THERAPY, BY TYPE, 2018-2030 (USD MILLION)
TABLE 32 EUROPE: RETINA HEALTH MARKET, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 33 GERMANY: RETINA HEALTH MARKET, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 34 GERMANY: RETINA HEALTH MARKET FOR THERAPY, BY TYPE, 2018-2030 (USD MILLION)
TABLE 35 GERMANY: RETINA HEALTH MARKET, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 36 UK: RETINA HEALTH MARKET, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 37 UK: RETINA HEALTH MARKET FOR THERAPY, BY TYPE, 2018-2030 (USD MILLION)
TABLE 38 UK: RETINA HEALTH MARKET, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 39 FRANCE: RETINA HEALTH MARKET, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 40 FRANCE: RETINA HEALTH MARKET FOR THERAPY, BY TYPE, 2018-2030 (USD MILLION)
TABLE 41 FRANCE: RETINA HEALTH MARKET, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 42 ITALY: RETINA HEALTH MARKET, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 43 ITALY: RETINA HEALTH MARKET FOR THERAPY, BY TYPE, 2018-2030 (USD MILLION)
TABLE 44 ITALY: RETINA HEALTH MARKET, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 45 SPAIN: RETINA HEALTH MARKET, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 46 SPAIN: RETINA HEALTH MARKET FOR THERAPY, BY TYPE, 2018-2030 (USD MILLION)
TABLE 47 SPAIN: RETINA HEALTH MARKET, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 48 REST OF EUROPE: RETINA HEALTH MARKET, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 49 REST OF EUROPE: RETINA HEALTH MARKET FOR THERAPY, BY TYPE, 2018-2030 (USD MILLION)
TABLE 50 REST OF EUROPE: RETINA HEALTH MARKET, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 51 ASIA-PACIFIC: RETINA HEALTH MARKET, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 52 ASIA-PACIFIC: RETINA HEALTH MARKET, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 53 ASIA-PACIFIC: RETINA HEALTH MARKET FOR THERAPY, BY TYPE, 2018-2030 (USD MILLION)
TABLE 54 ASIA-PACIFIC: RETINA HEALTH MARKET, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 55 JAPAN: RETINA HEALTH MARKET, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 56 JAPAN: RETINA HEALTH MARKET FOR THERAPY, BY TYPE, 2018-2030 (USD MILLION)
TABLE 57 JAPAN: RETINA HEALTH MARKET, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 58 CHINA: RETINA HEALTH MARKET, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 59 CHINA: RETINA HEALTH MARKET FOR THERAPY, BY TYPE, 2018-2030 (USD MILLION)
TABLE 60 CHINA: RETINA HEALTH MARKET, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 61 INDIA: RETINA HEALTH MARKET, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 62 INDIA: RETINA HEALTH MARKET FOR THERAPY, BY TYPE, 2018-2030 (USD MILLION)
TABLE 63 INDIA: RETINA HEALTH MARKET, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 64 AUSTRALIA: RETINA HEALTH MARKET, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 65 AUSTRALIA: RETINA HEALTH MARKET FOR THERAPY, BY TYPE, 2018-2030 (USD MILLION)
TABLE 66 AUSTRALIA: RETINA HEALTH MARKET, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 67 SOUTH KOREA: RETINA HEALTH MARKET, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 68 SOUTH KOREA: RETINA HEALTH MARKET FOR THERAPY, BY TYPE, 2018-2030 (USD MILLION)
TABLE 69 SOUTH KOREA: RETINA HEALTH MARKET, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 70 REST OF ASIA-PACIFIC: RETINA HEALTH MARKET, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 71 REST OF ASIA-PACIFIC: RETINA HEALTH MARKET FOR THERAPY, BY TYPE, 2018-2030 (USD MILLION)
TABLE 72 REST OF ASIA-PACIFIC: RETINA HEALTH MARKET, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 73 REST OF THE WORLD: RETINA HEALTH MARKET, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 74 REST OF THE WORLD: RETINA HEALTH MARKET, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 75 REST OF THE WORLD: RETINA HEALTH MARKET FOR THERAPY, BY TYPE, 2018-2030 (USD MILLION)
TABLE 76 REST OF THE WORLD: RETINA HEALTH MARKET, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 77 MIDDLE EAST: RETINA HEALTH MARKET, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 78 MIDDLE EAST: RETINA HEALTH MARKET FOR THERAPY, BY TYPE, 2018-2030 (USD MILLION)
TABLE 79 MIDDLE EAST: RETINA HEALTH MARKET, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 80 AFRICA: RETINA HEALTH MARKET, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 81 AFRICA: RETINA HEALTH MARKET FOR THERAPY, BY TYPE, 2018-2030 (USD MILLION)
TABLE 82 AFRICA: RETINA HEALTH MARKET, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 83 LATIN AMERICA: RETINA HEALTH MARKET, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 84 LATIN AMERICA: RETINA HEALTH MARKET FOR THERAPY, BY TYPE, 2018-2030 (USD MILLION)
TABLE 85 LATIN AMERICA: RETINA HEALTH MARKET, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 86 MAJOR PLAYERS IN THE GLOBAL RETINA HEALTH MARKET
TABLE 87 MOST ACTIVE PLAYERS IN THE GLOBAL RETINA HEALTH MARKET
TABLE 88 PRODUCT LAUNCH/PRODUCT APPROVAL
TABLE 89 MERGER & ACQUISITIONS
TABLE 90 EXPANSION
TABLE 91 AGREEMENT/MARKETING STRATEGIES
TABLE 92 NOVARTIS AG: PRODUCTS OFFERED
TABLE 93 NOVARTIS AG: KEY DEVELOPMENTS
TABLE 94 SPARK THERAPEUTICS, INC.: PRODUCTS/SERVICES OFFERED
TABLE 95 SPARK THERAPEUTICS, INC.: KEY DEVELOPMENTS
TABLE 96 GENSIGHT BIOLOGICS: PRODUCTS OFFERED
TABLE 97 ALLERGAN PLC: PRODUCTS/SERVICES OFFERED
TABLE 98 ALLERGAN PLC: KEY DEVELOPMENTS
TABLE 99 OXFORD BIOMEDICA PLC: PRODUCTS/SERVICES OFFERED
TABLE 100 HEMERA BIOSCIENCES LLC: PRODUCTS/SERVICES OFFERED
TABLE 101 HEMERA BIOSCIENCES LLC: KEY DEVELOPMENTS
TABLE 102 SANTEN PHARMACEUTICALS INC.: PRODUCTS OFFERED
TABLE 103 SANTEN PHARMACEUTICALS INC.: KEY DEVELOPMENTS
TABLE 104 REGENXBIO INC.: PRODUCTS OFFERED
TABLE 105 REGENXBIO INC.: KEY DEVELOPMENTS
TABLE 106 MEIRAGTX LIMITED: PRODUCTS OFFERED
TABLE 107 APPLIED GENETIC TECHNOLOGIES CORPORATION (AGTC): PRODUCTS OFFERED
?

LIST OF FIGURES
FIGURE 1 MARKET SYNOPSIS
FIGURE 2 GLOBAL RETINA HEALTH MARKET
FIGURE 3 BOTTOM-UP AND TOP-DOWN APPROACHES
FIGURE 4 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL RETINA HEALTH MARKET
FIGURE 5 DRIVER IMPACT ANALYSIS
FIGURE 6 RESTRAINTS IMPACT ANALYSIS
FIGURE 7 VALUE CHAIN ANALYSIS: GLOBAL RETINA HEALTH MARKETMARKET
FIGURE 8 PORTER'S FIVE FORCES ANALYSIS: GLOBAL RETINA HEALTH MARKET
FIGURE 9 GLOBAL RETINA HEALTH MARKET, BY TREATMENT, 2021 & 2030 (USD MILLION)
FIGURE 10 GLOBAL RETINA HEALTH MARKET SHARE, BY TREATMENT (%), 2021
FIGURE 11 GLOBAL RETINA HEALTH MARKET, BY DISEASE INDICATION, 2021 & 2030 (USD MILLION)
FIGURE 12 GLOBAL RETINA HEALTH MARKET SHARE, BY DISEASE INDICATION (%), 2021
FIGURE 13 GLOBAL: RETINA HEALTH MARKET, BY REGION 2021 & 2030 (USD MILLION)
FIGURE 14 GLOBAL: RETINA HEALTH MARKET SHARE, BY REGION 2021 (%)
FIGURE 15 NORTH AMERICA: RETINA HEALTH MARKET SHARE, BY COUNTRY 2021 (%)
FIGURE 16 EUROPE: RETINA HEALTH MARKET SHARE, BY COUNTRY 2021 (%)
FIGURE 17 ASIA-PACIFIC: RETINA HEALTH MARKET SHARE, BY COUNTRY 2021 (%)
FIGURE 18 REST OF THE WORLD: RETINA HEALTH MARKET SHARE, BY COUNTRY 2021 (%)
FIGURE 19 BENCHMARKING OF MAJOR COMPETITORS
FIGURE 20 MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN THE GLOBAL RETINA HEALTH MARKET
FIGURE 21 GLOBAL RETINA HEALTH MARKET: COMPETITIVE LANDSCAPE
FIGURE 22 SALES (USD MILLION), 2021
FIGURE 23 RESEARCH & DEVELOPMENT EXPENDITURE 2021
FIGURE 24 NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 25 NOVARTIS AG: SWOT ANALYSIS
FIGURE 26 ALLERGAN PLC: SWOT ANALYSIS
FIGURE 27 OXFORD BIOMEDICA PLC: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 28 HEMERA BIOSCIENCES LLC: SWOT ANALYSIS
FIGURE 29 SANTEN PHARMACEUTICALS INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 30 SANTEN PHARMACEUTICALS INC.: SWOT ANALYSIS
FIGURE 31 REGENXBIO INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 32 REGENXBIO INC.: SWOT ANALYSIS
FIGURE 33 MEIRAGTX LIMITED: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 34 APPLIED GENETIC TECHNOLOGIES CORPORATION (AGTC): FINANCIAL OVERVIEW SNAPSHOT